Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose - Wikidata - wikimedia - TriplyDB

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

http://www.wikidata.org/entity/Q29547886

about

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis Treatment of hepatitis C in children: a systematic review Strategies to reduce hepatitis C virus recurrence after liver transplantation Hepatitis C: a review for primary care physicians Nitazoxanide for chronic hepatitis C Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Nitazoxanide for chronic hepatitis C virus infection Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response Ribavirin monotherapy for chronic hepatitis C Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C Ribavirin plus interferon versus interferon for chronic hepatitis C Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C Ribavirin plus interferon versus interferon for chronic hepatitis C Outcomes of treatment for hepatitis C virus infection by primary care providers Boceprevir for previously treated chronic HCV genotype 1 infection An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial Kinetics of hepatitis C virus RNA load during pegylated interferon alpha-2a and ribavirin treatment in naïve genotype 1 patients Safety and Efficacy of Adding Ribavirin to Interferon or Peginterferon in Treatment of Hepatitis C Infection in Patients With Thalassemia: A Systematic Review on Randomized Controlled Trials KASL clinical practice guidelines: management of hepatitis C Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy Impact of new treatment options for hepatitis C virus infection in liver transplantation Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin Hepatitis C cirrhosis: New perspectives for diagnosis and treatment Hepatitis C virus (HCV) infection in Africa: a review Dendritic cell-based immunity and vaccination against hepatitis C virus infection Review of patient-reported outcome measures in chronic hepatitis C Antiviral treatment of hepatitis C virus infection and factors affecting efficacy Review article: HCV genotype 3 – the new treatment challenge Update on the treatment of patients with non-genotype 1 hepatitis C virus infection Emerging therapies for the treatment of hepatitis C Liver safety assessment in special populations (hepatitis B, C, and oncology trials)Future classes of hepatitis C virus therapeutic agents The place of immunotherapy in the management of HCV-induced vasculitis: an update

P2860

Q21132564-2BC9A79F-7921-4684-94C3-2A428E696FD9 Q21136318-C4D987B6-1BA8-4657-85D6-E2091700BBE2 Q22305418-D7465E82-42F8-4548-AAA4-470A264423DF Q22306040-76302198-962C-49B1-8CA1-5A352A6A9E17 Q24197485-93B907FA-0320-4AF4-A5A6-5E0B6AAADAFD Q24200189-51244BFE-122D-499A-ABAD-4FB44A59F4EF Q24200197-0F3AA61B-1B0B-40E8-BF58-69C9CBA61314 Q24200534-8C6518EF-ED5F-4C3B-BE69-5350E8E80801 Q24234215-409B97DB-01E4-4CA5-9A93-434C82968A64 Q24235606-F55D572B-986A-4F5E-8503-29CB0C8B6FD9 Q24240057-AC0D1748-F2C9-4DDD-A602-A77EFB185E76 Q24240315-320C8638-0707-4FCD-AC3F-9DF0D4F6A4CB Q24240879-5B57DABC-F07C-499A-BD6A-68AB1682D16D Q24240929-334CA941-E276-408D-B2E0-374C83E2B757 Q24241360-61641134-4BF1-46DA-9C1C-800D87D260A9 Q24244070-322B9F2C-FD2C-4057-879C-41AC00B5195B Q24601722-F550D517-6BC6-44E2-B060-01229BAD3616 Q24620576-B93EA25D-6D8C-4879-8444-052E10DA46A0 Q24632766-C39ECD20-2C03-48CF-8899-250163F21AFF Q24644729-636907A1-6D3B-4FB3-B6E3-D81F659457F6 Q24683611-16791478-4F77-4CBC-BCBC-40165D4E64B2 Q25257004-302CAF68-74CD-475A-AAB1-AC6724053FF2 Q26745895-1FC949C3-403D-4129-B665-54BB708CA2A4 Q26752471-7F6190FD-C54A-4AA6-80BE-D8BF6E09FF6A Q26768128-C4A3D711-9092-456A-9D28-6D45FFC5A5DB Q26777408-99BB9CC0-3688-45A2-B1FB-258CA33D149A Q26781481-4C345E52-64F4-45B6-B1DB-1526ECC30D88 Q26782017-160A2DBA-E645-4A0F-94F7-9AB5D08012B7 Q26784321-2E3BCF97-99BC-4F44-97CF-53A2096144E1 Q26799924-891B645D-822B-41EA-9170-52BF6FF30F33 Q26824322-9CCE2868-2476-42C6-B755-BC2372B0B9FD Q26828003-CB87B84B-0EDA-49A1-859B-79FBB5079ACC Q26828825-05D50708-F4E1-40F9-A7F2-F140200FECFF Q26851810-640689EE-FFBB-4E11-B17A-891413E0D154 Q26864571-BD5DBDCE-1618-42A9-A83F-4EAD9FE1F08A Q27000806-717D8EB8-5822-4DDE-B685-C96E6B4BDD17 Q27003319-FB696439-9899-4F3A-A0DC-A52E716EBD74 Q27008502-B1673DD4-964B-41B8-AC16-103A522EF985 Q27009321-2431A547-286C-4052-9683-0B0BA8B99D61 Q27015124-4BED0853-9CEB-4651-997B-8EBFE3F2608F

P2860

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

http://www.wikidata.org/entity/Q29547886

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@ast

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@en

type

label

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@ast

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@en

prefLabel

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@ast

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@en

P1433

Q29547886-54302FA4-9F6F-4793-B053-EBD5B50288FC

P1476

Q29547886-4FE4C2D4-9D75-4EB1-A56D-860972C3ED01

P2093

Q29547886-0B81DEF8-4300-437E-B9AE-ED5B5049260F

Q29547886-12AF00EA-4A75-4BC3-8D47-32D78039819F

Q29547886-1F2B8FE2-7456-4F3F-B9A8-CE317887EBEC

Q29547886-21FB5DE7-3C81-46B4-A31C-82C3582913CE

Q29547886-2A52B41A-A6CB-4056-A0E0-2DD927E3C89F

Q29547886-672E55DD-CD72-443B-B90E-A205CA2B76E5

Q29547886-7978BA9A-0CAF-4926-A658-4B7A111C4FD6

Q29547886-92D60EB6-28A2-4060-8E4F-95C0B4D021CB

Q29547886-B14DC3AF-5A23-49AB-A10D-CBA97964B423

Q29547886-B5B70A60-46BA-45B7-AF54-5B464EEB5647

P304

Q29547886-982D4BA5-06C4-4A76-9358-66D30B3CEADE

P31

Q29547886-E85932DC-3773-4CB5-90D8-F2B4CB8CD135

P3181

Q29547886-F7ED16EC-9764-476E-A20D-730D71D4DB07

P356

Q29547886-F8776D8B-2DFC-4CAF-AD56-F5EBACB5E605

P407

Q29547886-006D686B-23EB-4E38-B399-9B40271BD408

P433

Q29547886-BC0CF525-3D3B-4B10-BFF4-ACCFC1609880

P478

Q29547886-42A9F26C-175D-49AE-AE89-8123587088F1

P577

Q29547886-C9FA6A1F-3EFE-45FC-AFD9-D91076185F95

P698

Q29547886-7143B77F-08D1-4EBC-8E2F-BFE218FDA882

P3181

P356

0003-4819-140-5-200403020-00010

P1433

Annals of Internal Medicine

P1476

Peginterferon-alpha2a and riba ...... nt duration and ribavirin dose

@en

P2093

Ackrill AM

http://www.w3.org/2001/XMLSchema#string

Balan V

http://www.w3.org/2001/XMLSchema#string

Bernstein D

http://www.w3.org/2001/XMLSchema#string

Bodenheimer H Jr

http://www.w3.org/2001/XMLSchema#string

Diago M

http://www.w3.org/2001/XMLSchema#string

Hadziyannis SJ

http://www.w3.org/2001/XMLSchema#string

Lin A

http://www.w3.org/2001/XMLSchema#string

Marcellin P

http://www.w3.org/2001/XMLSchema#string

Morgan TR

http://www.w3.org/2001/XMLSchema#string

Pockros PJ

http://www.w3.org/2001/XMLSchema#string

P304

346-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1204051

http://www.w3.org/2001/XMLSchema#string

P356

10.7326/0003-4819-140-5-200403020-00010

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14996676

http://www.w3.org/2001/XMLSchema#string